New drug delivery system targets bladder cancer in early trial
NCT ID NCT05567185
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 23 times
Summary
This early-phase study tests a new treatment called TAR-210 in 5 Japanese patients with bladder cancer that has specific genetic changes (FGFR mutations). The treatment is placed directly into the bladder to deliver the drug erdafitinib. The main goal is to check safety and tolerability, not to cure the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for URINARY BLADDER NEOPLASMS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Osaka International Cancer Institute
Osaka, 541 8567, Japan
-
St Marianna University Hospital
Kanagawa, 216 8511, Japan
-
Toyama University Hospital
Toyama, 930-0194, Japan
-
University of Tsukuba Hospital
Tsukuba, 305 8576, Japan
Conditions
Explore the condition pages connected to this study.